Skip to main content

Loading market ticker...

A

Ashish Agarwal

Ashish Agarwal brings over 15 years of experience in technical analysis and automated signal–driven market strategies, specialising in equity and commodities markets across the UK, Australia, and India. He holds an MBA in Finance and a degree in Data Science, combining market expertise with a strong data-driven approach. His core strengths include price action analysis, trend identification, momentum indicators, and systematic auto-signal frameworks. Known for his clear communication and structured analytical style, Ashish delivers insightful, technically focused market commentary. He joined the Kalkine team in April 2024, contributing high-quality research and informed global market perspectives.

Latest articles from Ashish Agarwal

  • Consumer
  • May 29, 2026
  • By Ashish Agarwal

Why Are Varroc Engineering Shares Under Pressure Despite 238% Profit Growth and Record Business Wins?

Why Are Varroc Engineering Shares Under Pressure Despite 238% Profit Growth and Record Business Wins?

  • News
  • May 29, 2026
  • By Ashish Agarwal

Why Is TIL Witnessing Sharp Profit Booking After Latest Results? (NSE: TIL)

Why Is TIL Witnessing Sharp Profit Booking After Latest Results? (NSE: TIL)

  • News
  • May 29, 2026
  • By Ashish Agarwal

Raj TV Stock Cracks 10%: What Do Technical Indicators Suggest Now? (NSE: RAJTV)

Raj TV Stock Cracks 10%: What Do Technical Indicators Suggest Now? (NSE: RAJTV)

  • News
  • May 29, 2026
  • By Ashish Agarwal

Why Is Jaykay Enterprises Seeing Sharp Selling After Posting Q4 Numbers? (NSE: JAYKAY)

Why Is Jaykay Enterprises Seeing Sharp Selling After Posting Q4 Numbers? (NSE: JAYKAY)

  • News
  • May 29, 2026
  • By Ashish Agarwal

Delta Corp Shares Crash 14%: Is the Gaming Stock Losing Momentum?

Delta Corp Shares Crash 14%: Is the Gaming Stock Losing Momentum?

  • News
  • May 29, 2026
  • By Ashish Agarwal

Strong Revenue, Weak Stock? Why Lincoln Pharmaceuticals Is Under Pressure (NSE: LINCOLN)

Strong Revenue, Weak Stock? Why Lincoln Pharmaceuticals Is Under Pressure (NSE: LINCOLN)